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Abstract
Background: Mutations in GBA cause Gaucher disease when biallelic and are strong 
risk factors for Parkinson's disease when heterozygous. GBA analysis is complicated 
by the nearby pseudogene. We aimed to design and validate a method for sequencing 
GBA using long reads.
Methods: We sequenced GBA on the Oxford Nanopore MinION as an 8.9 kb ampli-
con from 102 individuals, including patients with Parkinson's and Gaucher diseases. 
We used NanoOK for quality metrics, NGMLR to align data (after comparing with 
GraphMap), Nanopolish and Sniffles to call variants, and WhatsHap for phasing.
Results: We detected all known missense mutations in these samples, including the 
common p.N409S (N370S) and p.L483P (L444P) in multiple samples, and nine rarer 
ones, as well as a splicing and a truncating mutation, and intronic SNPs. We demon-
strated the ability to phase mutations, confirm compound heterozygosity, and assign 
haplotypes. We also detected two known risk variants in some Parkinson's patients. 
Rare false positives were easily identified and filtered, with the Nanopolish quality 
score adjusted for the number of reads a very robust discriminator. In two individuals 
carrying a recombinant allele, we were able to detect and fully define it in one carrier, 
where it included a 55‐base pair deletion, but not in another one, suggesting a limita-
tion of the PCR enrichment method. Missense mutations were detected at the correct 
zygosity, except for the case where the RecNciI one was missed.
Conclusion: The Oxford Nanopore MinION can detect missense mutations and an 
exonic deletion in this difficult gene, with the added advantages of phasing and in-
tronic analysis. It can be used as an efficient research tool, but additional work is 
required to exclude all recombinants.
K E Y W O R D S
Gaucher disease, GBA, long‐read sequencing, mutation detection, mutation phasing, Oxford Nanopore 
MinION, Parkinson’s disease
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1 |  INTRODUCTION
The GBA gene (OMIM #606463) encodes the lysosomal 
enzyme Glucocerebrosidase, deficiency of which leads 
to accumulation of glucosylceramide. Biallelic (homozy-
gous or compound heterozygous) mutations in GBA cause 
Gaucher disease (GD), the most common lysosomal storage 
disorder (Schapira, Chiasserini, Beccari, & Parnetti, 2016). 
Heterozygous GBA mutations are a significant risk factor for 
Parkinson's disease (PD; Mullin & Schapira, 2015; Sidransky 
et al., 2009), with evidence of longitudinal changes in many 
carriers suggestive of prodromal PD (Beavan et al., 2015). 
GBA mutations are also associated with dementia with 
Lewy bodies (Geiger et al., 2016) and multiple system at-
rophy (MSA; Mitsui et al., 2015), related conditions which 
also demonstrate aggregation of the alpha‐synuclein pro-
tein. At present, more than 300 mutations have been linked 
to Gaucher disease (Hruska, LaMarca, Scott, & Sidransky, 
2008), and the number of studies analyzing the prevalence 
and phenotype of GBA mutations in PD is rapidly increasing 
(Adler et al., 2017; Alcalay et al., 2015; Berge‐Seidl et al., 
2017; Liu et al., 2016).
GBA comprises eleven exons and ten introns over ~8 kb 
on chromosome 1q21. A nearby pseudogene GBAP has 
96% exonic sequence homology to the GBA coding region. 
The region also contains the Metaxin gene (MTX1) and its 
pseudogene. The existence of these two pseudogenes confers 
an increased risk for recombination between homologous 
regions, which can generate complex alleles. The homology 
between GBA and GBAP is highest between exons 8 and 11, 
where most of the pathogenic mutations have been reported, 
usually resulting from recombination events (Hruska et al., 
2008).
The complex regional genomic structure complicates 
PCR and DNA sequencing, and some exons are also prob-
lematic in exome sequencing (Mandelker et al., 2016) and 
whole genome sequencing (Bodian et al., 2016). Established 
analysis protocols usually involve PCR of up to three frag-
ments, carefully designed to not amplify GBAP (Neumann 
et al., 2009), followed by Sanger sequencing of coding 
exons. Illumina targeted sequencing protocols have also re-
cently been developed (Liu et al., 2016; Zampieri, Cattarossi, 
Bembi, & Dardis, 2017). In recent years, long reads produced 
by sequencing DNA molecules in real time have become 
commercially available and have several advantages over 
short reads (Goodwin, McPherson, & McCombie, 2016). 
Oxford Nanopore sequencing technology analyses a single 
DNA molecule while it passes through a pore, producing 
characteristic changes in current depending on the sequence 
(Ip et al., 2015). The Oxford Nanopore MinION is currently 
the most portable long‐read sequencer. It can be plugged 
into a computer through a USB connection and provides se-
quencing data and runs metrics data in real time. It has been 
used for applications ranging from pathogen sequencing in 
the field (Quick et al., 2016) to sequencing a whole human 
genome (Jain et al., 2018). It is still not routinely used in 
human disease diagnostics, but has been successfully used 
for SNV detection in CYP2D6, HLA‐A, and HLA‐B (Sović et 
al., 2016); TP53 in cancer (Crescenzio Francesco Minervini 
et al., 2016); and BCR‐ABL1 in leukemia (Crescenzio F. 
Minervini et al., 2017). SNPs were successfully typed in 
chromosome 20 in a recent whole genome sequencing study 
of the NA12878 genome (Jain et al., 2018).
In the present study, we present and validate an efficient 
laboratory and bioinformatic protocol for GBA analysis using 
the MinION. In addition to disease‐causing variants, it can 
detect intronic ones and provide phasing information. The 
MinION protocol can thus provide further insights into GBA 
than other sequencing technologies and is ready to be consid-
ered for diagnostic use.
2 |  MATERIALS AND METHODS
2.1 | Overview, DNA extraction, and PCR
Samples successfully used in this study were derived from 
102 individuals. All samples shown to carry mutations are 
shown in Supporting Information Table S1. We used samples 
from saliva of 93 living individuals, and from brain from nine 
(seven PD and one MSA patients, and one control). Brain 
samples were provided by Queen Square and Parkinson's UK 
brain banks. SNV analyses were performed blinded to disease 
status and any previous sequencing results from the patient 
or relatives. All individuals had given written informed con-
sent. Ethics approval was provided by the National Research 
Ethics Service London—Hampstead Ethics Committee, with 
additional permission for study of brains from the research 
tissue banks provided by the UK National Research Ethics 
Service (07/MRE09/72). DNA was isolated from brain using 
phenol–chloroform (Nacheva et al., 2017) and from saliva 
using Oragene DNA Kit.
We enriched for GBA by amplifying an 8.9‐kb sequence, 
which covered all coding exons, the introns between them, and 
part of the 3’ UTR region (chr1: 155,202,296–155,211,206; 
Supporting Information Figure S1). We customized previously 
reported primers (Jeong et al., 2011) to carry Oxford Nanopore 
adapters and barcodes for multiplexing. Primer sequences 
were npGBA‐F: 5’‐TTTCTGTTGGTGCTGATATTGC 
TCCTAAAGTTGTCACCCATACATG‐3’ and npcMTX1: 
5’‐ ACTTGCCTGTCGCTCTATCTTCCCAACCTTTCTTC 
CTTCTTCTCAA‐3’.
Two DNA polymerases with appropriate optimized 
PCR conditions were used to amplify the GBA target re-
gion (Supporting Information Table S2): Expand Long 
Template PCR (Roche) and Kapa Hi‐Fi Polymerase (Kapa 
Biosystems). Amplicons were purified by Qiaquick PCR 
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Purification Kit (Qiagen), and DNA concentration was mea-
sured by Qubit.
2.2 | Barcoding, library 
preparation, and sequencing
For sample multiplexing, a barcoding step was carried out 
after generating the GBA amplicons with PCR Barcoding 
Expansion Kit 1 (up to 12 samples) or 96 (up to 96 samples) 
(Oxford Nanopore). We used the manufacturer amplicon se-
quencing protocol, starting with 1 µg of DNA and 1% ƛDNA 
CS spike‐in for the dA‐tailing step, followed by purification 
using AMPure beads. Nanopore adapters were ligated to the 
end‐prepped DNA, using the NEB blunt/TA ligase master 
mix recommended by the manufacturer. Flow cell priming 
was performed according to the requirements of each flow 
cell version. We first used R7.3 and R9 flow cells with 2D 
reads, where a molecule passes through the pore in both di-
rections. After recent technical advances, we used 1D reads 
from R9.4 flow cells.
2.3 | Bioinformatic analysis
MinKNOW versions 0.51.1.62 and later were used for 
data acquisition and run monitoring. Metrichor versions 
v2.38.1033–v2.40.17 were used for basecalling, de‐mul-
tiplexing, and fast5 file generation. The software divides 
reads into “pass” and “fail,” and only “pass” reads were ana-
lyzed. We used NanoOK (version 1.25; Leggett, Heavens, 
Caccamo, Clark, & Davey, 2015) to obtain a wide range of 
quality control metrics. This was combined with GraphMap 
alignment (version 0.3.0; Sović et al., 2016), using the pre-
cise region targeted as reference. We first converted fast5 
files to fastq using NanoOK or Poretools (version 0.6.0; 
Loman & Quinlan, 2014) with a 2‐kb size cutoff. NanoOK 
output included the N50 (the size at which reads of the same 
or greater length contain 50% of the bases sequenced), the 
commonest erroneous substitutions, and overall error es-
timates, notably the aligned base identity excluding indels 
(ABID), and identical bases per 100 aligned bases includ-
ing indels (IBAB). We aligned reads to the human genome 
(hg19) for detailed study and variant calling using GraphMap 
or NGMLR (version 0.2.6; Sedlazeck et al., 2018), both spe-
cifically developed for long reads. SAMtools (version 1.3.1) 
was used where required to merge, sort, downsample, and 
index bam files. Coverage was calculated using BEDtools 
(version 2.25.0; Quinlan, 2014). Data were viewed on IGV 
(version 2.3.9).
We used Nanopolish (versions 0.6‐dev and 0.8.4; 
Quick et al., 2016) to call variants over our target region. 
Nanopolish was specially developed to improve accuracy 
by reanalysis of raw signals after alignment and used in a 
recent whole genome study (Jain et al., 2018). It relies on 
a hidden Markov model which calculates the probability of 
the MinION data at the signal level for a given proposed se-
quence (Loman et al., 2015). Crucially, the nanopore does 
not call each base individually, but emits a signal which de-
pends on the several bases (likely six), which are traversing 
the pore at any given moment. Candidate SNPs are consid-
ered within the context of all possible haplotypes. For each 
subset of candidate SNPs, the haplotype with the largest 
likelihood is called the sequence for the region. Any vari-
ants in the called haplotype are assigned a quality score, 
which is the log likelihood ratio between the called haplo-
type and the reference sequence in that region. We called 
variants setting ploidy to 2 and invoked the “fix homopoly-
mers” option. When using Nanopolish 0.8.4, we had to use 
Albacore (version 2.1.3, Oxford Nanopore) to generate 
fastq files for analysis. We filtered any indel calls smaller 
than five bases, due to the known problem of nanopore in 
calling these, especially in homopolymer regions (Jain et 
al., 2018; Sedlazeck et al., 2018). We reviewed the variant 
quality of all calls and visualized them on IGV. We used 
WhatsHap (version 0.17; Martin et al., 2016), designed to 
phase missense mutations in long reads and tag bam files 
for visualization. We used Sniffles (version 1.0.7), another 
tool designed specifically for such data, to call structural 
variants (Sedlazeck et al., 2018).
All bioinformatic commands and the bed file for exons 
are given in Appendix. Variant nomenclature is based on the 
Human Genome Variation Society guidelines (den Dunnen et 
al., 2016) using GenBank reference sequence NM_000157.3. 
The traditional numbering for GBA missense mutations, 
which omits the first 39 amino acids, is given in brackets to 
ensure easy comparability with previous literature. SNVs 
were annotated using ANNOVAR (version 2017–07–17; 
Wang, Li, & Hakonarson, 2010) and viewed on www.var-
some.com, which provides data from dbSNP, gnomAD (Lek 
et al., 2016) genomes and exomes where available, and other 
useful metrics.
2.4 | Sanger sequencing
Sanger sequencing was performed at Source BioScience 
(UK). For exons 9–11, we performed PCR to enrich for this 
part of the gene with primers Fragment 8–11 Forward and 
Reverse (Stone et al., 2000). PCR was performed on the 
amplified GBA gene unless otherwise specified. Primers 9 
Forward and 10–11 Reverse were used for sequencing and 
provided good quality data from exons 9 to 11 inclusive.
2.5 | Statistical analysis
This was performed using GraphPad Prism v.6.0 (GraphPad, 
CA, USA) using paired t test and Mann–Whitney analysis as 
indicated.
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3 |  RESULTS
3.1 | GBA missense mutation detection is 
possible in patients and carriers
We first performed sequencing using 2D reads on older 
nanopore chemistry versions R7.3 and R9. We confirmed 
read alignment to the gene and detected mutations in 
both known carriers, among nine brain samples tested 
(Supplementary Note 1; Supporting Information Figures 
S2–S4; Tables S3 and S4). With the rapid improvements in 
nanopore 1D chemistry and availability of R9.4 cells, we 
proceeded to testing more samples, mostly known to carry 
pathogenic mutations. We used the Kapa PCR protocol, 
because of a possible minimal error reduction (Supporting 
Information Table S4). We initially multiplexed 10 sam-
ples, eight of which were known to carry at least one 
mutation, including two previously tested PD brain sam-
ples carrying RecNciI and p.L483P to test reproducibility 
with the new chemistry. NanoOK analysis showed high 
base accuracy for all samples (mean 93.2%; Supporting 
Information Tables S3 and S5). We aligned data using 
both GraphMap, and the newly developed NGMLR, 
with a mean GBA coverage >300, and minimal number 
of reads aligning to the pseudogene (average 0.78% and 
1.97% of the reads aligning to gene with GraphMap and 
NGMLR, respectively; Supporting Information Table 
S5). Reads aligning to the pseudogene were reviewed 
using GenomeRibbon (Nattestad, Chin, & Schatz, 2016; 
Supporting Information Figure S5). We noted that in 
alignments by NGMLR, which splits long reads into 256‐
base fragments and aligns them independently, some reads 
appeared to be split between the gene and pseudogene. 
While these could in theory represent structural variants, 
but represented by a small number of reads, we consider 
chimeric molecules formed during PCR a far more likely 
explanation (Laver et al., 2016).
We called variants using Nanopolish (version 0.8.4) on 
data aligned both with GraphMap and with NGMLR. We 
detected all previously known coding missense mutations, 
at the correct zygosity, regardless of the aligner used (Table 
1; Figure 1). These included p.N409S (N370S) in three GD 
patients, in the homozygous state in two (S12, S14), and 
heterozygous in one (S17) (Figure 1a), and the second mu-
tation in S17 (p.L105P; Figure 1b). In another GD patient, 
we detected two other heterozygous pathogenic mutations 
(p.R502C, p.R535C; Figure 1c,d). In the “RecNciI” car-
rier (S5), in addition to the expected three coding SNVs, 
the p.D448H variant was reported (Figure 1f). We also 
detected heterozygosity in three samples from individuals 
T A B L E  1  Coding mutations detected
Genomic position Base change Amino acid change Old notation Individuals carrying Zygosity detected
155,209,547 c.314T>C p.L105P L66P 1 het
155,209,430 c.431T>G p.L144R L105R 1 het
155,208,060 c.626G>A p.R209P R170P 1 het
155,207,265 c.866G>T p.G289V G250V 1 het
155,207,230 c.901C>G p.R301G R262G 1 heta
155,206,167 c.1093G>A p.E365K E326K 2 hetb
155,206,068 c.1192C>T p.R398a R349Ta 1 het
155,206,037 c.1223C>T p.T408M T369M 1 hetb
155,205,634 c.1226A>G p.N409S N370S 22 hom/het
155,205,563 c.1297G>T p.V433L V396L 2 het
155,205,471 c.1388+1G>A Splicing IVS9+1C>T 2 het
155,205,542 
155,205,518 
155,205,043 
155,205,008 
155,204,994
c.[1263_1317del55; 
1342G>C; 
1448T>C; 
1483G>C; 
1497G>C]
p.L422Pfs*4 c.1263del+RecTL 1 het
155,205,043 c.1448T>C p.L483P L444P 9 het
155,205,034 c.1457T>A p.V486E V447E 1 het
155,204,794 c.1603C>T p.R535C R496C 1 het
155,204,987 c.1504C>T p.R502C R463C 1 het
Note. The old amino acid notation is included. The number of individuals carrying each mutation, and the zygosity in which they were detected, is shown (het = heterozy-
gous, hom = homozygous).
GenBank reference sequence NM_000157.3
aThis was initially assigned as homozygous, before RecNciI was detected (see text). bThese do not cause Gaucher disease, but are PD risk alleles. 
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without GD for p.L483P (L444P) (Figure 1e), including 
the one tested earlier. The Nanopolish mean quality score 
for coding heterozygous SNVs was 638 (standard devia-
tion [SD] 229), and the lowest was 337.8. Two previously 
untested samples (PD patient S16 and control S18) were 
negative.
3.2 | Noncoding SNVs are also detected, and 
rare false positives can be identified
We reviewed all other SNV calls and noted several known 
SNPs present in the heterozygous or homozygous state, 
with quality scores also >500 (supporting information Table 
S6). We also noted seven SNVs that were reported in one 
or (usually) several samples with lower quality scores (all 
but one <200), all but one intronic (Supporting Information 
Table S7). These were always transitions (G>A, A>G, or 
C>T). These base changes were identified as common er-
rors by NanoOK (occurring in 13.31%, 12.66%, and 11.95% 
on average of the relevant base, respectively). Furthermore, 
review of these positions on IGV in all samples revealed a 
high percentage of uncorrected reads with the aberrant base, 
including those where the SNV was not called (11%–31%; 
Supporting Information Figure S6). We concluded that these 
were false positives. Comparing the effect of the aligner on 
false positives, we noted that some were shared by GraphMap 
and NGMLR alignments from the same sample. Overall, 
however, the NGMLR alignments had significantly fewer 
false positives, mostly due to one SNP that was always called 
in GraphMap samples, but never in NGMLR (mean per sam-
ple 2.2 with GraphMap, and 1.2 with NGMLR; paired t test 
p = 0.0038).
To investigate false‐positive SNVs further, we re-
viewed k‐mer motifs which were prone to error ac-
cording to NanoOK for the commonest false positive 
(chr1: 155,211,111A>G, found in four samples; no. 7 in 
Supporting Information Figure S6). We noted that CAGC, 
where the third base corresponds to the base prone to error, 
was within the three commonest 4‐mer errors for substi-
tutions in all cases. Another G>A change found as a false 
positive in one sample (S1) was also affecting the third base 
in this 4‐mer. We did not notice any relation to common 
error in 5‐mers. We also reviewed strand bias and found an 
excess in false positives (p = 0.04; supplementary note 2). 
We noted several one base pair indels (deletions: mean 10, 
SD 1.41; insertions mean 0.2, SD 0.63) and did not analyze 
these any further, as small indel detection is not currently 
reliable.
F I G U R E  1  Missense mutations 
detected with R9.4 chemistry. The IGV trace 
is shown for each sample with a mutation. 
The mutated base is shown, with 20 bases 
on either side. The three SNPs which 
comprise RecNciI are shown in Figure 3c. 
GenBank reference sequence NM_000157.3
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3.3 | Nanopolish quality score adjusted for 
coverage discriminates true and false positives
To investigate the effect of coverage on mutation detection, we 
downsampled three samples (carrying five mutations in total). 
The Nanopolish quality score varied linearly with coverage for 
true positives, but all were still reported at mean base cover-
age of ~50 (Supporting Information Figure S7a). They could 
also be discerned on IGV, which we would always recommend 
as a supplementary check for reported variants (Supporting 
Information Figure S7b). We then generated the ratio of 
Nanopolish quality score to coverage, to determine whether this 
was a more reliable discriminator than the absolute value. This 
was essentially constant with downsampling in a given sample 
(Supporting Information Figure S7c). It could distinguish true 
and false positives more reliably than the unadjusted quality 
score as there was no overlap between true and false positives, 
being >1.8 for true‐positive and <1.2 for false calls (Supporting 
Information Tables S6, S7). The mean (and standard deviation) 
was 3.5 (SD 1.7) for all true‐positive heterozygote SNVs, 2.8 
(SD 1.1) for coding true positives, and 0.5 (SD 0.3) for false 
positives. In the two samples homozygous for p.N409S, the 
scores were 7.8 and 7.9, with 2.8 in a heterozygote.
3.4 | Structural variant detection and 
mutation phasing provide additional relevant 
information
Sniffles and Nanopolish both reported a 55‐bp exonic deletion 
in S5 in the NGMLR alignment only, clearly visible on IGV in 
this alignment, and verified by Sanger sequencing (Supporting 
Information Figure S8). This sample had been previously 
designated “RecNciI” based on the presence of three pseudo-
gene‐derived missense changes which comprise this genotype. 
In addition to the deletion, we detected the missense change 
p.D448H, both of which may coexist with the “RecNciI” muta-
tions. This allele is classified as “c.1263del+RecTL allele,” in-
dicating a different site of recombination with the pseudogene 
than RecNciI (Hruska et al., 2008). Detecting this deletion can 
be difficult with Illumina targeted sequencing (Zampieri et al., 
2017). No other structural variants were reported.
We next phased all variants using WhatsHap (Supporting 
Information Table S8). We verified that the four coding SNVs 
and the deletion in S5 were in cis, as well as five rare intronic 
SNPs already detected in the original analysis (Figure 2). We 
confirmed compound heterozygosity in two GD patients, S7, 
heterozygous for p.N409S and p.L105P, and S15, heterozygous 
for p.R502C and p.R535C. We noted a haplotype comprising 
eight SNPs over 6.7 kb. This corresponds to the previously re-
ported Pv1.1+/− haplotype (Beutler, West, & Gelbart, 1992), 
later extended to a 70‐kb haplotype designated 111 (Mateu et 
al., 2002). One sample was homozygous and two heterozy-
gous for Pv1.1+ (Supporting Information Table S8). p.N409S 
(N370S) was always on the Pv1.1− background, as expected 
(Hruska et al., 2008). The p.L483P (L444P) mutation was on 
the Pv1.1− haplotype in two individuals and the Pv1.1+ in one, 
consistent with the reported lack of founder effect (Hruska 
et al., 2008). p.L105P and the recombinant allele were on a 
Pv1.1− haplotype, and p.R502C and p.R535C on Pv1.1+.
3.5 | Further multiplexing allows an efficient 
workflow with detection of all missense variants, 
but one recombinant is missed
To increase cost‐effectiveness and detect any false‐positive 
or false‐negative calls in a larger number, we multiplexed 92 
more samples on a R9.4 flow cell. Although yields well over 
5 Gb are expected, this flow cell was used after 4 months 
with a total data yield <4 Gb. In preparation for diagnostic 
use, we focused on calls in GBA exons and the flanking 50 
bases. We considered 100 as the minimum mean coverage 
needed across these regions before performing analysis, 
which we obtained for 85 samples (mean coverage of 844, 
SD 525). These included 13 Gaucher disease patients, 11 rel-
atives, 53 PD patients, and eight controls, four of whom were 
relatives of PD patients. We detected several missense muta-
tions (Table 1) and confirmed that we had the same results 
as before for 12 of the Gaucher patients. One patient (bc74) 
appeared homozygous for p.R262G, but had been previously 
reported as a compound heterozygote with RecNciI (Duran et 
al., 2012). We performed Sanger sequencing after amplifying 
exons 9–11 directly from genomic DNA, which revealed the 
RecNciI SNVs. These were clearly absent in the nanopore se-
quence, and in Sanger sequencing from nested amplification 
of the initial amplicon, suggesting that our long‐range PCR 
protocol had not amplified this recombinant allele (Figure 3).
We detected one mutation in all but one GD relative, con-
sistent with the genotype of the previously analyzed affected 
relative. In one sample from an obligate carrier, we did not 
find any mutations with the MinION, or after Sanger sequenc-
ing exons 9–11 (where we expected a mutation) after either 
nested or direct amplification from genomic DNA. We could 
not exclude sample mix‐up. Six of the PD patients (11.3%) 
were heterozygotes for known disease‐causing mutations, or 
alleles which increase the risk of PD, despite not being patho-
genic for Gaucher (two p.E326K, one p.T369M; Berge‐Seidl 
et al., 2017). In addition, to exclude false negatives in the exons 
where most mutations occur, we performed Sanger sequenc-
ing of exons 9–11 for 35 negative samples. All were negative.
3.6 | The reliability of the adjusted 
Nanopolish score is confirmed
We downsampled four samples, carrying six coding vari-
ants (three p.N409S, two p.L483P, and one p.E365K), by 
factors of 2, 4, and 10. Once again, we observed that the 
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quality score varied linearly with coverage, but the adjusted 
quality score (divided by the number of reads) remained es-
sentially constant (Supporting Information Figure S9). We 
reviewed all calls on IGV as before and noted an average of 
1.8 false positives per sample, often repeated across sam-
ples. From seven total different false positives, five had 
not been seen before, but all were still transitions (Table 
S9). The Nanopolish quality score adjusted for the number 
of reads was once again a clear discriminant between true‐ 
and false‐positive SNVs (Supporting Information Tables 
S1, S9). For true‐positive heterozygotes, it was always 
>2.0 (mean 4.07, SD 1.2). For false positives, it was <1.6 
(mean 0.19, SD 0.26) and even lower when the new false 
positives only were considered (mean 0.14). This suggests 
that the increased coverage led to additional false positives, 
but with low quality, and therefore easy to filter. We noted 
that the adjusted quality score appeared to vary with the 
mutation, with p.N409S significantly higher than p.L483P 
(mean 4.13 v 2.65; Mann–Whitney p = 0.001). The mean 
score was also higher than in the previous run, although 
this was partly due to the different mutations. To determine 
reproducibility of this score between runs, we compared 
F I G U R E  2  Detection and phasing of a 55‐base pair exonic deletion in S5. The coverage track, with eight SNVs highlighted, and a selection 
of reads are shown, over exons 9 and 10 (chr1:155,204,981–155,205,661; NGMLR alignment). The deletion is clearly visible as a drop in coverage 
(red bracket). Reads are grouped and colored by haplotype for these variants, which are all on the blue‐colored reads. The arrows point to the SNVs 
(red = coding, blue = noncoding) and the red box to the deletion. GenBank reference sequence NM_000157.3
F I G U R E  3  Evaluation of recombinant detection. A–C: IGV summary views over the region, including uncorrected allele frequencies at the 
three SNV positions. A: Nanopore sequencing does not detect even low levels of the three SNVs in bc74. B: Sample without RecNciI shown for 
comparison. C: The three RecNciI SNVs in this exon are clearly seen in sample S4 which carries RecTLdel55. D‐E: Sanger sequencing of exon 
9–11 amplicon from bc74. D: When amplified directly from genomic DNA, RecNcil SNVs are seen (arrows). E: These are absent in nested PCR 
from GBA amplicon used for nanopore sequencing
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the p.L483P heterozygote scores in six samples from this 
and three from the previous run, but the difference in this 
small sample size was not significant (mean 2.65 v 2.2; 
Mann–Whitney p = 0.1). We thus confirmed the ability 
of the adjusted Nanopolish quality score to discriminate 
true and false positives, and provided some evidence that 
this depends on the mutation, although the score may vary 
somewhat between experiments.
4 |  DISCUSSION
We have sequenced a long‐range GBA amplicon, covering 
all coding exons and introns, using the Oxford Nanopore 
Technologies MinION. We analyzed 95 samples using 1D 
chemistry on R9.4 flow cells, including 32 already known 
or expected to carry biallelic or heterozygous mutations, in a 
blinded fashion. We confirmed common mutations (p.N409S, 
p.L483P) in several samples, differentiating p.N409S ho-
mozygosity and heterozygosity. We were in total specifically 
able to detect the p.N409S in 4 homozygous and 19 heterozy-
gous carriers, and p.L483P in nine heterozygotes. We also 
detected 12 other pathogenic mutations (nine missense, one 
splicing, one truncating, and one recombinant) and two mis-
sense variants which are PD risk factors. We did not detect a 
recombinant allele present in one sample.
Recent years have seen the introduction of single‐mole-
cule sequencing in real time by Oxford Nanopore and PacBio 
which can easily generate long reads of several kb (Goodwin 
et al., 2016), and in the case of the nanopore up to hundreds 
of kb (Jain et al., 2018). Using long reads has several advan-
tages, despite the lower accuracy at the base level (Goodwin 
et al., 2016), some of which were evident here. The challenge 
of aligning short reads to regions with high homology is often 
not fully appreciated (Mandelker et al., 2016), with false neg-
atives in GBA‐targeted Illumina sequencing when the whole 
genome was used as a reference (Zampieri et al., 2017). We 
observed minimal alignment to the pseudogene. We also de-
tected intronic SNPs, an understudied area in GBA, and other 
lysosomal disorders (Zampieri et al., 2017). Finally, the long 
reads allowed the phasing of mutations, enabling a haplo-
type‐resolved personalized assessment. This helps overcome 
the frequent problem of phasing, which may require analysis 
of relatives (Tewhey, Bansal, Torkamani, Topol, & Schork, 
2011), as in other GBA studies (Alcalay et al., 2015).
The nanopore chemistry, and bioinformatic tools avail-
able, has evolved considerably during the time in which this 
work was performed. We compared two aligners (GraphMap 
and the more recently developed NGMLR), both of which 
gave negligible alignment to the pseudogene. We were able 
to identify and filter SNV false positives, based on (1) the low 
quality on Nanopolish, (2) the high % of these changes oc-
curring as errors based on NanoOK (with some evidence of 
the k‐mers carrying them also being over‐represented), and 
(3) the significant percentage of aberrant bases at the same 
positions in all samples, even where not called as mutations. 
Notably, they were always transitions, which were also the 
main errors in whole genome sequencing using the MinION 
(Jain et al., 2018). NGMLR allowed for the detection of the 
55‐bp deletion and halved the number of false positives. We 
thus recommend using NanoOK for quality control when 
testing or developing a protocol, NGMLR for alignment, 
Nanopolish for SNV calling, and Sniffles for structural vari-
ant calling. Nanopolish has been designed for SNV calling 
by correcting accuracy problems arising in nanopore default 
basecalling by reanalyzing the raw signal data (Jain et al., 
2018). Nanopolish variant calling option uses a likelihood‐
based method to generate haplotypes that serve as the ref-
erence sequence for the target region (Quick et al., 2016). It 
has been instrumental in projects ranging from Ebola virus 
(Quick et al., 2016) to human genome sequencing (Jain et 
al., 2018).
We noted that the ratio of the Nanopolish quality score 
divided by the total number of reads over that base remained 
almost constant with downsampling and was a very strong 
discriminator of true and false positives. This adjusted qual-
ity score should be useful to others analyzing this or other 
genes, particularly if samples with known mutations are 
used as controls to “benchmark” and correct for any subtle 
variation due to different laboratory or bioinformatic proto-
cols. We found that coverage >100 × detected all missense 
and splicing variants, with no false positives after filtering. 
Much higher coverage slightly increased the false positives, 
but the additional ones had very low adjusted quality scores. 
Downsampling showed that lower coverage (~50×) may be 
adequate, but we have not validated it, particularly for zy-
gosity determination. In a human whole genome sequencing 
study, coverage of only ~30x allowed SNP calling on chro-
mosome 20 by Nanopolish with accuracy ~95%, but zygos-
ity was not always correctly determined (Jain et al., 2018). 
Coverage of GBA was poor, so we cannot comment on SNP 
detection (Supporting Information Figure S10).
Current known nanopore limitations include the inability 
to accurately resolve homopolymers and detect small inser-
tions and deletions (indels) (Jain et al., 2018; Sedlazeck et 
al., 2018), and we did not attempt to do this, filtering several 
single base pair indel calls. Sniffles can detect larger inser-
tions and deletions, as demonstrated here, as well as com-
plex structural variants (Sedlazeck et al., 2018). Based on the 
rapid developments in the chemistry and bioinformatics, we 
expect calling of small indels and further reduction of false‐
positive SNV calls in the near future.
We only detected one of two GBA recombinant alleles. 
These may arise from gene conversion (nonreciprocal recom-
bination) or gene fusion with reciprocal recombination (Tayebi 
et al., 2003). The latter event leads to two configurations: 
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fusion between the gene and the pseudogene with a deletion 
of part of the intergenic region, and a partial duplication of the 
gene and pseudogene, which are fused together. In our sam-
ples, the c.1263del55+RecTL allele detected appears to be 
arising from gene conversion, and hence, this allele was am-
plified by our primers (Supporting Information Figure S11). 
The RecNcil allele not detected in one sample appears to have 
arisen as a fusion/deletion allele, with the region where our 3’ 
long‐range primer binds deleted. Determination of exon dos-
age by qPCR would help confirm this interpretation (Spataro 
et al., 2017). Detection of recombinants is a known problem. 
RecNciI can be missed by targeted Illumina sequencing, unless 
specifically aligning reads to GBA, rather than the whole ge-
nome (Zampieri et al., 2017). Recombinant alleles have been 
reported in PD, with frequencies of 0.7% (Liu et al., 2016) 
and 0.25% (Neumann et al., 2009), and may be the fifth com-
monest GBA variant in non‐Ashkenazi PD patients (Zhang et 
al., 2018). The frequency of all rearrangements affecting GBA 
may be even higher, as they were found in 1.6% of PD patients 
in one study with extensive analysis of exome data (Spataro et 
al., 2017). Another recent study with a combined short‐read 
and Sanger approach did not report any recombinants in 735 
PD patients (Ruskey et al., 2018), but at least one likely re-
combinant, RecN370S, appears to have been missed. Other 
large PD studies used a variety of methods and did not report 
recombinant alleles, which could have been missed (Jesús et 
al., 2013; Kalinderi et al., 2009; Winder‐Rhodes et al., 2013). 
Detection of all recombinants would be possible with addi-
tional long‐range PCR using different primers, which would 
only yield a product if gene fusion events were present (Jeong 
et al., 2011). These products could then be sequenced on the 
MinION (or by Sanger). Ultimately, enrichment for long frag-
ments across the entire region without PCR, for example by 
a CRISPR approach (Gabrieli et al., 2018), will allow com-
prehensive long‐read sequencing of all possible recombinants.
As treatments are now available, neonatal screening for 
lysosomal storage diseases is becoming commoner (Minter 
Baerg et al., 2017), including in some cases Gaucher (Burton 
et al., 2017; Hopkins et al., 2015). This relies on biochemical 
activity, often by blood‐spot screening (Johnson, Dajnoki, & 
Bodamer, 2014), with several false positives in Gaucher, pos-
sibly due to carrier status (Hopkins et al., 2015). Genetic con-
firmation is ultimately required, so a rapid and cost‐effective 
method would be useful in this setting. The advantages of the 
MinION include the very low capital cost, space requirements, 
and turnaround time of the analysis. The cost per sample is 
likely to compare favorably with Sanger and Illumina sequenc-
ing in all settings, especially taking into account the ability to 
phase variants, although Sanger validation would be sensible 
at least initially. Current R9.4 flow cells yields are at least 5 Gb 
of sequence and often much more. For our 8.9 kb amplicon, 
96 samples, which is the maximum that can currently be mul-
tiplexed on a single flow cell, would therefore achieve a mean 
coverage >1,000×, well in excess of what is needed, even if 
less than a fifth of the reads aligned successfully.
Oxford Nanopore is a versatile single‐molecule real‐
time sequencing technology that has been used in several 
innovative applications, from detection of Ebola to proof‐
of‐principle human whole genome sequencing. Here, we 
demonstrate that the MinION can detect and phase patho-
genic variants in GBA, and intronic SNPs that would not 
be detected by Sanger sequencing of exons. The rapid 
evolution of specific bioinformatic methods, and the im-
provements in accuracy and data yield, combined with 
the minimal footprint and capital investment, makes the 
MinION a suitable platform for long‐read sequencing of 
difficult genes such as GBA, both in the diagnostic and 
in the research environments, although additional PCR or 
other enrichment methods may be needed to detect a par-
ticular class of recombinants.
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APPENDIX 
SUMMARY OF BIOINFORMATIC 
COMMANDS
ALBACORE TO CONVERT TO FASTQ
read_fast5_basecaller.py ‐‐flowcell FLO‐MIN106 ‐‐kit SQK‐
LSK108 ‐‐barcoding ‐‐output_format fastq ‐‐input/path/to/.
fast5 ‐‐save_path/path/to/output ‐‐worker_threads 8 ‐r
NANOOK FOR QC
nanook align ‐s path/sample directory ‐r path/ref.fasta ‐
aligner graphmap
nanook analyse ‐s path/sample directory ‐r path/ref.fasta ‐
passonly ‐aligner graphmap
GRAPHMAP TO ALIGN
graphmap align ‐r reference.fa ‐d reads.fasta ‐o output.sam
NGMLR TO ALIGN
ngmlr ‐r/path/to/reference.fa ‐q/path/to/merged/.fastq 
‐o/path/to/.bam
SAMTOOLS TO SORT AND INDEX BAM 
FILES
samtools sort/path/to/.bam>/path/to/.sorted.bam
samtools index/path/to/.sorted.bam
NANOPOLISH TO CALL VARIANTS
nanopolish index ‐d path/to/.fast5 path/to/.fastq
nanopolish variants ‐g/path/to/reference.fa ‐r/path/to/
merged/.fastq ‐b/path/to/sorted.bam ‐‐ploidy 2 ‐w "1:155,202,239– 
155,216,653" ‐o/path/to/.vcf ‐‐snps ‐‐fix‐homopolymers
ANNOVAR TO ANNOTATE THE VARIANTS 
CALLED
perl table_annovar.pl/path/to/.vcf humandb/‐buildver hg19 
‐‐protocol avsnp150 ‐‐operation f ‐nastring.‐‐outfile/path/to/
annovar.vcf ‐‐polish ‐vcfinput ‐remove
VCFTOOLS TO REMOVE INDELS
vcftools ‐‐vcf/path/to/annovar.vcf ‐‐out/path/to/noindels.vcf 
‐‐remove‐indels ‐‐recode ‐‐recode‐INFO‐all
TABIX TO CONVERT TO GZ AND INDEX 
(GZI) BEFORE USING VCFTOOLS
bgzip/path/to/noindels.vcf
tabix ‐p vcf/path/to/.gz
VCFTOOLS TO MERGE ALL.VCF FILES 
 TOGETHER (FOR EASIER REVIEW OF 
OUTPUT FROM RUN 1D‐2)
vcf‐merge/path/to/*.gz > merged.vcf
BEDTOOLS TO CALCULATE MEAN 
 COVERAGE OVER DESIRED REGION
coverageBed ‐mean ‐a/pathto/file.bed ‐b/pathto/sorted.bam
BCFTOOLS TO FILTER THE MERGED  
VCF FILE WITH THE BED FILE FOR 
EXONS
bcftools filter ‐R/path/to/.bed/path/to/merged.vcf.gz ‐o/path/
to/filtered.vcf
BED FILE CO‐ORDINATES USED TO LIMIT 
CALLS TO EXONS IN RUN 1D‐2
1 155,210,904 155,211,119 5’UTR
1 155,210,827 155,210,903 exon1
1 155,210,371 155,210,558 exon2
1 155,209,627 155,209,918 exon3
1 155,209,357 155,209,603 exon4
1 155,208,258 155,208,491 exon5
1 155,207,875 155,208,147 exon6
1 155,207,082 155,207,419 exon7
1 155,205,986 155,206,310 exon8
1 155,205,422 155,205,685 exon9
1 155,204,936 155,205,152 exon10
1 155,204,786 155,204,941 exon11
1 155,204,189 155,204,785 3’UTR
